GRI Bio (GRI), a biotechnology company, on Tuesday reported interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for Idiopathic Pulmonary Fibrosis or IPF.
The study demonstrated that GRI-0621 (4.5mg, taken orally once daily) was safe and well-tolerated in the first 12 patients evaluated. No significant changes were observed in LDL, HDL, triglyceride, or total cholesterol (TG) levels, as assessed at the 2-week visit.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.